trial

Huperzine for Cognitive and Functional Impairment in Schizophrenia

NCTId NCT00963846
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 56 (actual)
Sponsored by Biomedisyn Corporation
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
56 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-03
Primary completion
2012-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
huperzine 0.2 mg BIDhuperzine 0.4 mg BIDhuperzine 0.8 mg BID

Sponsors

Biomedisyn CorporationLead Sponsor
Yale UniversityCollaborator

Investigators

1
Scott W. Woods, MDPrincipal Investigator

Sites

1 total
New Haven, United States

Linked catalysts

1
Huperzine for Cognitive and Functional Impairment in Schizophrenia — primary completion2012-12

Facts & assertions

4 sourced
Enrollment
56
Phase
PHASE2
Primary Completion Date
2012-12
Status
COMPLETED
relationships
The graph out of here
drug
huperzine 0.2 mg BID
drug
huperzine 0.4 mg BID
drug
huperzine 0.8 mg BID
drug
lead_sponsor
Biomedisyn Corporation
company
collaborator
Yale University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Scott W. Woods, MD
person